Production and purification of a chimeric monoclonal antibody against botulinum neurotoxin serotype A

Authors

Mark C. Mowry, Department of Chemical and Biomolecular Engineering, University of Nebraska, 207 Othmer Hall, 820 North 16th Street, Lincoln, NE 68588, USA
Michael Meagher LEAD INVESTIGATOR, University of Nebraska-LinolnFollow
Leonard Smith, Toxinology and Aerobiology Division, US Army Medical Research Institute of Infectious Diseases, Frederic, MD 21702, USAFollow
Anuradha Subramanian, Department of chemical Engineering,University of Nebraska Lincoln.Follow

Date of this Version

October 2004

Comments

This article was published in Protein Expression and Purification, Volume 37, Issue 2 , October 2004, Pages 399-408, doi:10.1016/j.pep.2004.06.022 Copyright © 2004 Elsevier Inc. All rights reserved. Please visit the Publishers website for the published version

Abstract

Production of recombinant antibodies against botulinum neurotoxin is necessary for the development of a post-exposure treatment. CHO-DG44 cells were transfected with a plasmid encoding the light and heavy chains of a chimeric monoclonal antibody (S25) against botulism neurotoxin serotype A. Stable cell lines were obtained by dilution cloning and clones were shown to produce nearly equivalent levels of light and heavy chain antibody by an enzyme-linked immunosorbent assay (ELISA). In suspension culture, cells produced 35 μg/ml of chimeric antibody after 6 days, corresponding to a specific antibody productivity of 3.1 pg/cell/day. A method for the harvest and recovery of an antibody against botulism neurotoxin serotype A was investigated utilizing ethylenediamine-N,N′-tetra(methylphosphonic) acid (EDTPA) modified zirconia and MEP-hypercel, a hydrophobic charge interaction chromatography resin. Purification of the S25 antibody was compared to that achieved using rProtein A–Sepharose Fast Flow resin. After the direct load of culture supernatant, analysis by ELISA and gel electrophoresis showed that S25 antibody could be recovered at purities of 41 and 44%, from the EDTPA modified zirconia and MEP-hypercel columns, respectively. Although the purity obtained from each of these columns was low, the ability to withstand high column pressures and nearly 90% recovery of the antibody makes EDTPA modified zirconia well suited as an initial capture step. Combining the EDTPA modified zirconia and HCIC columns in series resulted in both purity and final product yield of 72%.